Leadership & Board

Dr. Cheri Walker is a senior life sciences and diagnostics executive with more than 25 years of experience spanning executive leadership, commercialisation, corporate development, financial markets, strategy and mergers and acquisitions. She has worked with public and private companies, management teams, private equity and venture capital firms to develop and execute strategies for business growth, commercial expansion and value creation.

Dr. Walker brings extensive experience across the diagnostics and life sciences sectors, including point-of-care diagnostics, IVD, regulatory and quality systems, commercialisation and international market development. She has successfully led and advised businesses through periods of significant growth and has been involved in more than 45 completed mergers, acquisitions and divestitures.

Prior to joining Atomo's executive leadership, Dr. Walker served as a senior executive and entrepreneur across a range of life science and diagnostics businesses. She was Chief Executive Officer of Zeta Corporation, a recombinant immunohistochemistry antibody company, and President, Chief Executive Officer and Director of Rhinostics, an early-stage diagnostics company based on technology initially developed at Harvard University. She has also held senior leadership positions at Abcam, Charles River Laboratories, QIAGEN and Life Technologies, now part of Thermo Fisher Scientific, and earlier in her career worked in the financial markets as a life sciences stock analyst. Additionally, she has strong financial experience serving as Chief Financial Officer of Kailos Genetics and started her career as a stock analyst at Deutsche Bank covering the life science tools sector.

Dr. Walker joined the Atomo Board in 2022 and served as Chair of the Audit and Risk Committee before being appointed Executive Director and Interim Chief Executive Officer in August 2026. In this role, she is leading Atomo through its next phase of commercial growth, with a particular focus on expanding the Company's presence in the United States, Europe and other international markets, accelerating commercial execution and building on Atomo's differentiated point-of-care diagnostics platform.

Dr. Walker holds a BA in Biology from Swarthmore College and a PhD in Human and Molecular Genetics from Baylor College of Medicine.

Chandra joined Atomo in 2017 as Director of Programs bringing with her more than 25 years of experience within the medical device industry. She has extensive experience in the development of medical devices from conception to commercialisation. Prior to joining Atomo, she served in a variety of leadership roles within ResMed, including supply chain management, global manufacturing, and APAC marketing. Chandra holds a Bachelors Honours degree in Physics and an executive MBA from AGSM.

An experienced Non-Executive Director and Chair with Over 35 years of experience as a senior executive in medical devices & point-of-care diagnostics sectors within various multinational, private and listed biotechnology companies. Previously served as Non-Executive Director & Chair at Workplace Drug Testing Australasia Ltd and eWaste Connection Ltd. Currently a Committee Member at the University Animal Ethics Committee, QUT. A Fellow of the Australian Institute of Company Directors and holds degrees in Applied Science and Marketing.

Mr May has held various Director roles across international corporations including Hoechst Germany, Microgenics Corporation USA, Fisher Scientific and Thermo Fisher Scientific. With extensive experience across public and private pathology laboratories, as well as sales and management roles in the IVD supply sector, he has built a strong track record in business leadership and strategic growth. Mr May is a member of the Australasian Association for Clinical Biochemistry and Laboratory Medicine and holds a bachelor’s degree in science.